Details for New Drug Application (NDA): 208694
✉ Email this page to a colleague
The generic ingredient in ZERVIATE is cetirizine hydrochloride. There are thirty-nine drug master file entries for this compound. One hundred and fifty-six suppliers are listed for this compound. Additional details are available on the cetirizine hydrochloride profile page.
Summary for 208694
Tradename: | ZERVIATE |
Applicant: | Harrow Eye |
Ingredient: | cetirizine hydrochloride |
Patents: | 4 |
Pharmacology for NDA: 208694
Mechanism of Action | Histamine H1 Receptor Antagonists |
Medical Subject Heading (MeSH) Categories for 208694
Suppliers and Packaging for NDA: 208694
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694 | NDA | Eyevance Pharmaceuticals | 71776-024 | 71776-024-01 | 5 VIAL, SINGLE-USE in 1 CARTON (71776-024-01) / .2 mL in 1 VIAL, SINGLE-USE |
ZERVIATE | cetirizine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 208694 | NDA | Eyevance Pharmaceuticals | 71776-024 | 71776-024-05 | 1 BOTTLE, DROPPER in 1 CARTON (71776-024-05) / 5 mL in 1 BOTTLE, DROPPER |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | EQ 0.24% BASE | ||||
Approval Date: | May 30, 2017 | TE: | RLD: | Yes | |||||
Patent: | 8,829,005*PED | Patent Expiration: | Sep 15, 2030 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Patent: | 9,254,286*PED | Patent Expiration: | Jan 9, 2033 | Product Flag? | Substance Flag? | Delist Request? | Y | ||
Patent: | 9,750,684 | Patent Expiration: | Mar 15, 2030 | Product Flag? | Y | Substance Flag? | Delist Request? |
Complete Access Available with Subscription